- Structure Therapeutics (NASDAQ:GPCR) is developing an oral GLP-1 weight-loss pill that could offer an alternative to popular injectable treatments like Ozempic
- The company’s lead obesity drug, aleniglipron, helped patients lose up to roughly 16% of their body weight in clinical studies and continues advancing toward Phase 3 trials
- While still a smaller player than Novo Nordisk and Eli Lilly, Structure could become a significant competitor in the growing obesity drug market, with shares up more than 175% since July 2025 despite a challenging start to 2026
- Structure Therapeutics stock (NASDAQ:GPCR) opened trading at US$50.76
The global obesity treatment market is rapidly becoming one of the most closely watched sectors in healthcare, creating enormous opportunities for pharmaceutical companies developing next-generation weight-loss therapies. While industry leaders Novo Nordisk and Eli Lilly have dominated headlines with injectable treatments such as Wegovy, Ozempic, Zepbound, and Mounjaro, one smaller biotechnology company is working on a different approach.
Structure Therapeutics (NASDAQ:GPCR) is focused on developing oral small-molecule therapeutics for a range of diseases, including obesity. With a market capitalization of approximately US$3.5 billion, the company has emerged as an intriguing stock for investors seeking exposure to the growing GLP-1 market without investing directly in the industry’s largest players.
Betting on a weight-loss pill
At the heart of the investment thesis is the company’s effort to develop oral GLP-1 drugs, a category that many investors believe could represent the next major evolution in obesity treatment.
GLP-1 drugs, formally known as glucagon-like peptide-1 receptor agonists, are a class of medications designed to help lower blood sugar levels while also promoting weight loss. The success of medications such as Ozempic and Wegovy has transformed the treatment landscape for obesity and Type 2 diabetes, but most of today’s leading therapies are administered through injections.
Structure Therapeutics is attempting to tap into a potentially significant market opportunity by offering patients a pill instead of a needle. For many consumers, the ability to take a daily oral medication could remove one of the major barriers associated with injectable weight-loss treatments.
This article is a journalistic opinion piece that has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Promising clinical results
Investor interest in Structure increased significantly earlier this year following encouraging clinical trial data.
In March, the company reported that patients taking its once-daily obesity pill experienced approximately 16 per cent weight loss compared with placebo after 44 weeks of treatment. The results suggested that the company’s lead obesity candidate could potentially compete in an increasingly crowded but highly lucrative market.
While further trials will be needed to confirm these outcomes, the data demonstrated that oral therapies may be capable of delivering meaningful weight-loss results comparable to those achieved by some injectable treatments.
“The totality of efficacy and tolerability data across the Phase 2 program continue to demonstrate clear differentiation of aleniglipron, with the highest weight loss observed for an oral GLP-1RA to date and a safety profile appropriate for chronic use in a disease that impacts millions of people,” Structure Therapeutics’ CEO, Raymond Stevens, Ph.D, said in a media release. “The consistent weight loss observed across multiple studies to date reaffirms aleniglipron’s potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity.”
Nature medicine publication strengthens the story
The company’s development program gained additional credibility in June when Structure announced the publication of data from its Phase 2b ACCESS clinical trial in Nature Medicine.
The publication, titled “Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial,” detailed results for aleniglipron, the company’s oral small-molecule GLP-1 receptor agonist currently being developed for obesity treatment.
The published data highlighted efficacy across three maintenance dose levels in the Phase 2b ACCESS study while also presenting a predefined interim analysis from an open-label extension safety study.
Evidence of durable weight loss
One of the more encouraging aspects of the data was evidence that weight loss continued beyond the initial treatment period.
The open-label extension study demonstrated the durability of weight loss beyond 36 weeks and showed improved tolerability using a lower 2.5-milligram starting dose.
According to the interim analysis, patients continued losing weight after a median follow-up period of approximately 20 weeks. Participants who had previously received 45 mg, 90 mg, and 120 mg doses of aleniglipron recorded weight loss of 13.3 per cent, 16.2 per cent, and 15.3 per cent, respectively.
The findings provided additional support for the company’s upcoming Phase 3 program, which management expects to initiate during the third quarter of 2026.
Potential cardiovascular benefits
Beyond weight loss alone, the ACCESS study produced encouraging data regarding several cardiometabolic risk factors.
Structure reported improvements in:
- Systolic blood pressure
- Diastolic blood pressure
- High-sensitivity C-reactive protein (hsCRP)
- Waist circumference
- Hemoglobin A1c (HbA1c)
These improvements are important because cardiovascular health has become an increasingly significant factor in the commercial success of GLP-1 therapies. Existing approved GLP-1 drugs have demonstrated cardiovascular benefits, and investors will be closely watching whether aleniglipron can eventually show similar advantages.
Safety profile appears manageable
Like many GLP-1 medications, aleniglipron was associated primarily with gastrointestinal side effects.
According to the company, these adverse events were generally mild to moderate and tended to decrease over time. Most treatment discontinuations occurred during the initial dose-escalation period.
Notably, management reported no clear dose-response relationship among the most common gastrointestinal adverse events across treatment groups, while treatment discontinuations related to adverse events remained limited.
The company’s analysis also revealed an encouraging trend regarding vomiting events. Patients who required temporary dose interruptions or reductions typically did not experience recurring vomiting when treatment was restarted or doses were increased again.
That finding could prove important because long-term adherence remains one of the key challenges in obesity treatment. If patients are able to resume therapy successfully following temporary interruptions, they may be more likely to remain on treatment long enough to achieve meaningful weight-loss results.
A potential challenger emerges
Structure Therapeutics remains a speculative biotechnology investment, and substantial clinical, regulatory, and commercial hurdles remain ahead.
However, the company occupies a potentially attractive niche within the rapidly expanding obesity market. If future clinical trials confirm the efficacy and safety profile seen to date, Structure could emerge as a serious competitor to industry leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO).
The prospect of an effective oral weight-loss therapy has captured the attention of both patients and investors. While injectable GLP-1 drugs have already created tens of billions of dollars in value across the pharmaceutical sector, many believe a successful pill could further expand the addressable market by appealing to individuals who are reluctant to use injections.
For investors, that possibility helps explain why Structure Therapeutics remains one of the most closely watched emerging companies in the obesity drug space.
Despite the excitement surrounding its pipeline, Structure Therapeutics shares remain down more than 25 per cent since the beginning of the year. However, the stock has climbed nearly 10 per cent since May and has surged more than 175 per cent since July 2025, reflecting both the volatility and the significant long-term optimism surrounding its obesity drug program.
Structure Therapeutics stock (NASDAQ:GPCR) opened trading at US$50.76.
Join the discussion: Find out what the Bullboards are saying about Structure Therapeutics and check out Stockhouse’s stock forums and message boards.
